Ruxolitinib (NCT06991101)

Name: Ruxolitinib trial for Glioblastoma (NCT06991101)
Uploaded: 2026-10-31T15:38:25.241Z
Duration: 1 min 25 s
Description: Ruxolitinib trial for Glioblastoma (NCT06991101). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06991101.

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma: a one-minute explainerNCT069911011 min

Ruxolitinib trial for Glioblastoma (NCT06991101). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed IDH-wildtype glioblastoma. All MGMT methylation groups may qualify. Participants need adequate daily function and must be able to swallow tablets.

The idea: randomly add ruxolitinib to temozolomide chemotherapy and radiation. Ruxolitinib blocks JAK signaling involved in cell growth and inflammation. Initial treatment lasts six weeks, followed by a four-week break and maintenance treatment. Researchers compare survival and assess side effects. The control group receives chemotherapy and radiation without ruxolitinib.

This phase 2 study plans 190 patients. Manmeet Ahluwalia leads two recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.